the market is selling off this company because this company is clueless the correct strategy for successful drug development.
How many tiny weeney little trials they are going to do on -357 and waste time over there? Who the heck cares about PAD and MG? Why waste money there? Why didn't they do the drug-drug interaction studies upfront for ALS patients? It is a huge disappointment that they are proceeding with yet another time waster with the phase IIb ALS - low number of patients, not expect to have stats significance, short time span of treatment on and on.
These people are trying to snow investors with the number of trials they are running, but seriously, how many of these trials will lead to successful drug development and filings?
on the issue of -260 - again, who the heck the cares? Haven't they wasted enough time already?
Just focus on one thing and do that well instead of having so many trials and few if any provide good data. These people are wasting time, money, and investors' patience.
they need to cut down the R&D spending, focus on what is important.
hire someone bankers and outsource the development plan, get a partnership with -357.
They need to drastically reduce overhead and wait for their (and our) Omecantiv ship to come in. These trials for ALS are just this side of a waste of time. They don't have the money to take the ALS drug all the way, so they need to partner it with somebody who does. Why burn $50 million a year for all this "development" when they need to do a deal?